Summary
Generates evidence-backed oncology trial design recommendations using historical protocol analysis, endpoint benchmarking, and regulatory precedent.
Detailed Description
The Oncology Trial Design Pack synthesizes data from thousands of completed and ongoing oncology clinical trials to provide evidence-based recommendations for your trial design. It analyzes historical protocols registered on ClinicalTrials.gov, FDA oncology guidance documents, and published Phase 3 trial results to identify design patterns associated with regulatory success.
The pack evaluates your indication, line of therapy, and molecular target to recommend optimal primary and secondary endpoints, sample size benchmarks, control arm strategies, and stratification factors. It cross-references FDA oncology guidance on clinical trial endpoints for drugs and biologics with real approval outcomes.
Output includes a structured trial design rationale document with citations, a comparative analysis of precedent trials in your therapeutic niche, and an endpoint selection matrix scored by regulatory acceptance history and statistical feasibility.
Evidence Sources
| Source | Type | Description | Refresh |
|---|---|---|---|
| ClinicalTrials.gov | REGISTRY | Full registry of interventional oncology trials with protocol metadata, endpoints, and enrollment data | Weekly |
| FDA Oncology Guidance Library | REGULATORY | FDA guidance documents on clinical trial endpoints, tumor-specific development programs, and statistical considerations | Monthly |
| Published Phase 3 Protocols | LITERATURE | Peer-reviewed publications of Phase 3 oncology trial designs and results from major journals | Weekly |
Regulatory Mapping
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
Estimands and Sensitivity Analysis in Clinical Trials
Expansion Cohorts: Use in First-In-Human Clinical Trials
Agent Transparency
When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.
Evidence Retriever
brew-retriever-v3
Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.
Domain Analyzer
brew-domain-analyst-v2
Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.
Evidence Synthesizer
brew-synthesizer-v2
Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.
Output Validator
brew-validator-v1
Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.
Sample Outputs
Trial Design Rationale Document
PDFStructured evidence report justifying trial design choices with citations to precedent trials and regulatory guidance
Endpoint Selection Matrix
XLSXComparative matrix scoring candidate endpoints by regulatory acceptance, statistical power, and clinical meaningfulness
Precedent Trial Analysis
PDFDetailed comparison table of analogous completed trials including design features, outcomes, and regulatory decisions
Deliverables included
- Evidence-backed trial design rationale (15-25 pages)
- Endpoint benchmarking analysis with historical acceptance rates
- Comparative protocol table for 10+ precedent trials
- Sample size estimation based on observed effect sizes
- Regulatory precedent summary for pre-IND or EOP2 meetings
Related Disease & Biomarker Mappings
| Therapeutic Area | Disease Family | Key Biomarkers | Relevance |
|---|---|---|---|
| Solid Tumors | Non-Small Cell Lung Cancer | EGFRALKPD-L1KRAS G12C | Primary |
| Solid Tumors | Breast Cancer | HER2ER/PRBRCA1/2PIK3CA | Primary |
| Hematologic Malignancies | Acute Myeloid Leukemia | FLT3-ITDIDH1/2NPM1 | Secondary |
| Solid Tumors | Colorectal Cancer | KRAS/NRASBRAF V600EMSI-H/dMMR | Secondary |
Related Packs in Oncology
Dose Optimization Pack (Project Optimus)
Navigate the new dose optimization paradigm with confidence
Biomarker-Driven Trial Design Pack
Turn molecular insights into registration-ready trial designs
Immuno-Oncology Combination Pack
Build the regulatory case for your IO combination
Accelerated Approval Evidence Pack
Build a bulletproof accelerated approval submission
Version History
Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.
Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.
Initial draft — core evidence retrieval pipeline and output schema established.
Need a Custom Evidence Pack?
Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.
Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.